<DOC>
	<DOCNO>NCT01519908</DOCNO>
	<brief_summary>The purpose study investigate : relation set ( bio ) marker response Cardiac Resynchronization Therapy ( CRT ) ; interrelationship well potential predictive power ( bio ) marker improvement and/or deterioration cardiac function , cardiac geometry ( reverse re-modeling CRT ) evaluate . ( Bio ) marker include limited : collagen , genomic marker , molecular marker , electrocardiographic marker , echocardiographic marker , arrhythmogenic marker marker renal function : blood urea nitrogen ( BUN ) , serum creatinine , glomerular filtration rate ( GFR ) .</brief_summary>
	<brief_title>Markers Response Cardiac Resynchronization Therapy</brief_title>
	<detailed_description>Title MARC ( Markers And Response CRT ) - Prospective CRT study Sponsor study management The MARC study sponsor participant COHFAR project define COHFAR project agreement ( Medtronic , UMCU , AMC , MUMC , VUMC , UMCG ICIN ) . Study management do Medtronic . Purpose To investigate relation set ( bio ) marker response Cardiac Resynchronization Therapy ( CRT ) ; interrelationship well potential predictive power ( bio ) marker improvement and/or deterioration cardiac function , cardiac geometry ( reverse re-modeling CRT ) evaluate . ( Bio ) marker include limited : collagen , genomic marker , molecular marker , electrocardiographic marker , echocardiographic marker , arrhythmogenic marker marker renal function : blood urea nitrogen ( BUN ) , serum creatinine , glomerular filtration rate ( GFR ) . Design : This multi-center , exploratory , prospective , interventional post-market release , non-randomized , study . Medical device : For reason uniform therapy delivery homogeneity ( device diagnostic ) study data , Medtronic CRT-Defibrillator device use study CareLink transmission functionality , OptiVol Cardiac Compass report . Any commercially available lead use upon discretion investigator . All CRT-D device additional component ( lead , programmer ) incorporate study CE-marked market-released device use within intend use device . Objectives : Primary objective • To investigate relationship set ( bio ) marker response cardiac resynchronization therapy ( measure echocardiography ) 6 month . Secondary objective - To investigate relationship set ( bio ) marker response cardiac resynchronization therapy ( measure echocardiography ) 12 month - To investigate relationship ( bio ) marker atrial fibrillation follow-up - To investigate relationship ( bio ) marker ventricular tachycardia/ fibrillation and/or appropriate shock follow-up - To investigate relationship ( bio ) marker reverse remodel - To relate baseline cardiac anatomy , function mechanical dyssynchrony cardiac MR PET image subset patient CRT-response atrial ventricular arrhythmia . The biomarkers include : - Genomics ( blood cell ) : candidate gene approach micro-RNA 's ( analysis perform Genetics Core laboratory study end . A inal list micro-RNA 's determine study end ) . - Blood marker ( serum plasma ) limit : biomarkers fibrosis , inflammation , cardiac damage , hemodynamic stress extra-cardiac marker analyze Blood Biomarkers Core laboratory study end . - CMR Imaging baseline patient enrol VUMC , AMC UMCU investigational center : function , anatomy , hemodynamics , global local mechanical dyssynchrony assessment ( tag MR , CURE , torsion ) , Scar Imaging ( DCE-MRI ) measure . - PET Imaging patient enrol VUMC , AMC UMCU investigational center : Perfusion ( Adenosine ) , Innervation withHED tracer perform . - Electrocardiography : Beat-to-beat Variability Repolarization ( BVR ) / Short-Term Variability ( STV ) protocol - Echocardiography : function structure ( include limit LVEDD , LVESV , LVEDV , LVESVi , LVEF , MR , LVFT , IVMD , atrial volumina ) , combination electrocardiographic investigation : PA-TDI ( P-wave duration ) . Echo 2D-Speckle Tracking : Radial Strain , Septal Rebound Stretch , standard deviation Time peak systolic Strain ( final set parameter determine study end ) . - Clinical parameter include among coronary artery disease , Body Mass Index , gender , Myocardial Infarction baseline . All blood sample take peripheral venous blood implant also coronary sinus . Additional prospective analysis : - HF monitoring : intra-thoracic impedance ( Optivol ) , patient activity , heart rate variability , Cardiac Compass arrhythmic episode , continuously record Carelink - Electrical marker : arrhythmogenic marker ( final list marker determine study end ) . - Correlation AT/AF episodes detect Carelink baseline PA Tissue Doppler Imaging data . - Correlation echo strain measurement MRI strain measurement - Occurrence clinical event long-term follow-up ; clinical event include : - Cardiovascular hospitalization - Heart failure hospitalization - All-cause mortality - Heart transplantation - Acute implantation leave ventricular assist device - Atrial ventricular arrhythmia include atrial fibrillation , atrial flutter , atrial tachycardia , ventricular tachycardia , ventricular fibrillation , document continuous device diagnostic monitoring CareLink Subject selection : The study enroll 240 symptomatic heart failure patient ( NYHA functional class II-III ) reduce left ventricular ejection fraction prolong QRS duration measure prior implantation cardiac resynchronization device ( CRT-D ) . All patient follow 1 year implant . Each patient visit clinical site baseline , 1-month , 6-month 12 month follow-up . The total study duration 3 year . The 5 participate clinical institution locate Netherlands member COHFAR project partnership Center Translational Molecular Medicine ( CTMM ) Universitair Medisch Centrum Utrecht ( UMCU ) , Universitair Medisch Centrum Groningen ( UMCG ) , Academisch Medisch Centrum ( AMC ) , VU Medisch Centrum ( VUMC ) , Maastricht Universitair Medisch Centrum ( MUMC ) , Medtronic MSD support Dutch Heart Foundation . Treatment : Each study subject receive cardiac resynchronization therapy ( CRT-D ) accord ESC/AHA guideline per local hospital routine . Additionally , optimal medical therapy heart failure investigator 's discretion .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject indicate CRTD device accord current applicable ESC/AHA guideline Subject NYHA class II III Subject stable sinus rhythm ( atrial arrhythmia last &gt; 30 second last 2 week prior inclusion ) No documented AFepisodes allow last 2 week prior inclusion . Intrinsic QRSwidth ≥ 130 m LBBB ≥ 150 m without LBBB measure within 30 day prior device implant subject NYHA class II Intrinsic QRSwidth ≥ 120 m LBBB ≥ 150 m without LBBB measure within 30 day prior device implant subject NYHA class III Subject receive optimal heart failure oral medical therapy ( ACE inhibitor and/or ARB Beta Blockers ) , stable medication scheme least 1 month prior enrollment Subject willing sign inform consent form Subject 18 year old Subject upgrade bradycardia pacemaker CRTD Subject receive CRTD replacement upgrade CRTP CRTD Subject permanent atrial fibrillation/ flutter tachycardia . Subject experience recent myocardial infarction ( MI ) , within 40 day prior enrollment Subject underwent coronary artery bypass graft ( CABG ) valve surgery , within 90 day prior enrollment Subject post heart transplantation , actively list transplantation list , reasonable probability ( per investigator 's discretion ) undergo transplantation next year Subject implant leave ventricular assist device ( LVAD ) , reasonable probability ( per investigator 's discretion ) receive LVAD next year Subject chronic renal dialysis Subject severe renal disease ( defined Glomerular Filtration Rate ( GFR ) &lt; 30 mL/min/1.73m2 ) Subject continuous uninterrupted infusion ( inotropic ) therapy heart failure ( ≥ 2 stable infusion per week ) Subject RBBB Subject permanent 2nd 3rd degree AVblock Subject severe aortic stenosis ( valve area &lt; 1.0 cm2 significant valve disease expect operate within study period ) Subject complex uncorrected congenital heart disease Subject mechanical right heart valve Subject life expectancy le one year opinion investigator Pregnant breastfeeding woman , woman child bear potential reliable form birth control Subject enrol one concurrent study would confound result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>cardiac resynchronization therapy</keyword>
	<keyword>biomarkers</keyword>
	<keyword>response</keyword>
</DOC>